Skip to main content
Clinical Trials/ITMCTR2100005087
ITMCTR2100005087
Not yet recruiting
未知

The efficacy and safety of electroacupuncture in the treatment of Alzheimer's disease

Guang'anmen Hospital, China Academy of Chinese Medicine Sciences0 sitesTBD

Overview

Phase
未知
Intervention
Not specified
Conditions
Not specified
Sponsor
Guang'anmen Hospital, China Academy of Chinese Medicine Sciences
Status
Not yet recruiting
Last Updated
3 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
TBD
End Date
TBD
Last Updated
3 years ago
Study Type
Interventional study
Sex
All

Investigators

Sponsor
Guang'anmen Hospital, China Academy of Chinese Medicine Sciences

Eligibility Criteria

Inclusion Criteria

  • 1\. Meet the DSM\-IV\-R diagnostic criteria for dementia;
  • 2\. Meet the diagnostic criteria for probable AD in the NIA\-AA criteria;
  • 3\. Aged 50 to 85 years;
  • 4\. Clinical dementia assessment score \>\= 0\.5 points, MMSE score \<\= 26 points;
  • 5\. Hachinski ischemia scale score\<\=4 points;
  • 6\. It is allowed to have received ordinary acupuncture and electro\-acupuncture before screening, but has not received electro\-acupuncture in the past two weeks;
  • 7\. If the subject has the ability to make a decision, he/she shall sign the informed consent; if the patient's educational level is low and unable to sign the informed consent, the legal guardian shall sign the informed consent;
  • 8\. Caregivers or family members (guarantee to accompany the patient for \>\=3 hours a day, \>\=3 days a week) sign informed consent.

Exclusion Criteria

  • 1\. Accompanied by severe cerebrovascular disease;
  • 2\. Associated with other neurological or non\-neurological diseases that can cause cognitive dysfunction or progressive memory impairment;
  • 3\. Drug\-induced cognitive dysfunction or progressive memory impairment;
  • 4\. Inpatient or moderately high dependency nursing facility;
  • 5\. Patients with severe fear of needles, fainting of needles, and severe skin infections;
  • 6\. Patients with severe cardiovascular disease, malignant tumor, severe liver and kidney insufficiency;
  • 7\. Currently participating in other clinical trials.

Outcomes

Primary Outcomes

Not specified

Similar Trials